EFSA Rejects Quercetin Safety Case Above 250mg for Long Term Use in EU Supplements

The European Food Safety Authority has concluded that data supporting the safety of quercetin at daily intakes exceeding 250mg is insufficient. This ruling directly impacts companies currently selling 500mg or 1000mg capsules, as national authorities are expected to enforce these limits by January 2027.

Reformulation Strategies for Immunity Brands

For procurement managers, this shifts the cost structure. Pure quercetin dihydrate is currently priced at 88 EUR per kg for 95 percent purity. Moving to lower dosages will preserve margins, but brands must adjust their marketing to focus on bioavailability rather than load.

• Cap daily servings at 250mg to ensure regulatory compliance across all EU member states
• Switch to phytosomal or liposomal quercetin to maintain efficacy at the new lower legal limit
• Deplete high dose stock before the expected Q1 2027 enforcement deadline in the DACH region

Market Impact and Monitoring

Italy and Belgium have already signaled they will adopt the 250mg limit immediately for new notifications. If you are launching a longevity or immune complex in Q4, do not commit to 500mg formulations. You will likely face a recall or be forced to relabel within six months of launch.

Formulators should look at combining the 250mg quercetin limit with zinc and vitamin C to maintain the potency of the claim under Article 14. This keeps the product competitive without triggering the safety objections raised in the latest EFSA panel report.